MG
REGN icon

Mather Group’s Regeneron Pharmaceuticals REGN Stock Holding History

Mather Group’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$449K Sell
581
-133
-19% -$102K ﹤0.01% 521
2025
Q4 		$551K Buy
714
+272
+62% +$185K 0.01% 387
2025
Q3 		$249K Buy
+442
New +$250K ﹤0.01% 571
2025
Q2 		– Sell
-1,090
Closed -$691K – 1463
2025
Q1 		$691K Buy
1,090
+183
+20% +$126K 0.01% 314
2024
Q4 		$646K Sell
907
-65
-7% -$54.5K 0.01% 300
2024
Q3 		$1.02M Sell
972
-172
-15% -$191K 0.01% 242
2024
Q2 		$1.1M Buy
1,144
+95
+9% +$92.1K 0.01% 253
2024
Q1 		$921K Buy
1,049
+4
+0.4% +$3.8K 0.01% 235
2023
Q4 		$918K Sell
1,045
-14
-1% -$11.5K 0.01% 242
2023
Q3 		$872K Buy
1,059
+127
+14% +$99.8K 0.02% 237
2023
Q2 		$669K Buy
932
+560
+151% +$432K 0.01% 295
2023
Q1 		$305K Buy
372
+38
+11% +$28.7K 0.01% 393
2022
Q4 		$241K Buy
334
+11
+3% +$8.12K ﹤0.01% 432
2022
Q3 		$222K Buy
+323
New +$203K ﹤0.01% 433
2021
Q4 		– Sell
-477
Closed -$289K – 396
2021
Q3 		$289K Buy
+477
New +$296K 0.01% 228

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Mather Group's REGN Position: Q1 2026 in Review

Mather Group reduced its Regeneron Pharmaceuticals (REGN) stake by 19% in Q1 2026, selling an estimated $102K and leaving 581 shares worth $449K. The position accounts for ﹤0.01% of the portfolio, ranked #521.

Mather Group first reported a position in REGN in Q3 2021 and has held it in 15 quarters since. The position peaked at $1.1M in Q2 2024. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Mather Group held 581 shares of Regeneron Pharmaceuticals worth $449K as of Q1 2026.
  • Mather Group sold 133 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $102K.
  • Regeneron Pharmaceuticals made up ﹤0.01% of Mather Group's portfolio in Q1 2026, its #521 holding.
  • Mather Group first reported a position in Regeneron Pharmaceuticals in Q3 2021 and has held it in 15 quarters since.
  • Mather Group's Regeneron Pharmaceuticals position peaked at $1.1M in Q2 2024.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Mather Group's 13F filing for Q1 2026, filed 13 Apr 2026.